Summit Securities Group LLC lowered its position in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 96.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,134 shares of the biopharmaceutical company’s stock after selling 82,290 shares during the quarter. Summit Securities Group LLC’s holdings in Bristol Myers Squibb were worth $190,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of Bristol Myers Squibb by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 198,727,768 shares of the biopharmaceutical company’s stock worth $10,719,376,000 after buying an additional 2,743,759 shares during the period. State Street Corp increased its stake in shares of Bristol Myers Squibb by 1.4% during the fourth quarter. State Street Corp now owns 97,980,438 shares of the biopharmaceutical company’s stock valued at $5,285,065,000 after buying an additional 1,385,206 shares during the period. Geode Capital Management LLC raised its holdings in shares of Bristol Myers Squibb by 13.1% in the fourth quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock valued at $2,837,026,000 after acquiring an additional 6,084,046 shares in the last quarter. Norges Bank purchased a new stake in Bristol Myers Squibb in the fourth quarter worth about $1,947,272,000. Finally, AQR Capital Management LLC lifted its stake in Bristol Myers Squibb by 172.6% in the fourth quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company’s stock worth $1,391,485,000 after acquiring an additional 16,332,924 shares during the period. 76.41% of the stock is owned by institutional investors.
More Bristol Myers Squibb News
Here are the key news stories impacting Bristol Myers Squibb this week:
- Positive Sentiment: Bristol Myers Squibb was added to the Russell 1000 Defensive and Russell 1000 Value-Defensive indexes, which could broaden support from defensive and income-focused funds and reinforce its appeal as a lower-volatility dividend stock. Is Bristol Myers Squibb’s Shift Into Value-Defensive Indices Reshaping The Investment Case For BMY?
- Positive Sentiment: The company’s QUILS lung cancer detection initiative is expanding beyond Kentucky into other high-risk states, highlighting Bristol Myers Squibb’s broader oncology focus and potential reputational benefits for its public-health efforts. Bristol Myers Squibb (BMY) Expands QUILS Lung Cancer Detection Model Beyond Kentucky
Bristol Myers Squibb Stock Performance
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. The firm had revenue of $11.49 billion for the quarter, compared to the consensus estimate of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The company’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities analysts forecast that Bristol Myers Squibb Company will post 6.32 EPS for the current fiscal year.
Bristol Myers Squibb Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 4.4%. The ex-dividend date of this dividend is Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is currently 70.79%.
Analyst Ratings Changes
A number of research analysts have commented on BMY shares. UBS Group reissued a “buy” rating on shares of Bristol Myers Squibb in a research report on Thursday, May 28th. Bank of America lowered their price target on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating for the company in a research report on Thursday, April 9th. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 27th. Weiss Ratings reissued a “hold (c+)” rating on shares of Bristol Myers Squibb in a report on Thursday, July 2nd. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $54.00 target price on shares of Bristol Myers Squibb in a report on Monday. Eight investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of “Hold” and an average target price of $61.31.
Read Our Latest Stock Analysis on BMY
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.
BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.
Featured Articles
- Five stocks we like better than Bristol Myers Squibb
- PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth
- Dollar Tree’s Turnaround Is Starting to Take Root
- Why Levi’s Digital Strategy Is Paying Off in a Big Way
- Constellation Brands: Beer Growth and Buybacks Mask Stock’s Slump
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY – Free Report).
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
